Strategies to Overcome High-Risk Multiple Myeloma

被引：1

作者：

Sanchez, Larysa ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Multiple Myeloma Program, New York, NY 10029 USA

来源：

CANCER JOURNAL | 2021年 / 27卷 / 03期

关键词：

High risk; high-risk myeloma; myeloma; multiple myeloma; DARATUMUMAB PLUS LENALIDOMIDE; STEM-CELL TRANSPLANTATION; OPEN-LABEL; CONSOLIDATION THERAPY; DEXAMETHASONE; BORTEZOMIB; SURVIVAL; CARFILZOMIB; PREDNISONE; MELPHALAN;

D O I：

10.1097/PPO.0000000000000529

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma (MM) patients with high-risk cytogenetics continue to have inferior outcomes despite recent advances in the treatment of MM. As defined by the International Myeloma Working Group, the presence of t(4;14), t(14;16), del(17p), t(14;20) and amplification of 1q are considered to be high-risk chromosomal abnormalities associated with poor survival. Despite the use of immunomodulatory agents, proteasome inhibitors, autologous stem cell transplantation, and anti-CD38 monoclonal antibodies, clinical trials of current therapies have not shown strong statistical evidence of being able to overcome the poor prognosis of high-risk disease. Novel treatment approaches are urgently needed to improve survival in this subset of MM patients.

引用

页码：201 / 204

页数：4

共 50 条

[31] Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice [J].

Mizuguchi, Makiko ;

Okamoto, Yasunobu ;

Yagi, Hikaru ;

Kagawa, Kumiko ;

Sekimoto, Etsuko ;

Shibata, Hironobu ;

Shigekiyo, Toshio ;

Ozaki, Shuji .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (05) :718-728

[32] Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area [J].

Bianchi, Giada ;

Richardson, Paul G. ;

Anderson, Kenneth C. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (20) :2125-2132

[33] Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma [J].

Richardson, Paul G. ;

Sonneveld, Pieter ;

Schuster, Michael W. ;

Irwin, David ;

Stadtmauer, Edward A. ;

Facon, Thierry ;

Harousseau, Jean-Luc ;

Ben-Yehuda, Dina ;

Lonial, Sagar ;

San Miguel, Jesus-F. ;

Cavenagh, Jamie D. ;

Anderson, Kenneth C. .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (05) :429-435

[34] Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor [J].

Vela-Ojeda, J. ;

Garcia-Ruiz Esparza, M. A. ;

Padilla-Gonzalez, Y. ;

Sanchez-Cortes, E. ;

Garcia-Chavez, J. ;

Montiel-Cervantes, L. ;

Reyes-Maldonado, E. ;

Majluf-Cruz, A. ;

Mayani, H. .

ANNALS OF HEMATOLOGY, 2009, 88 (01) :59-66

[35] Multiple Myeloma: Defining the High-Risk Patient and Determining the Optimal Treatment Strategy [J].

Schecter, Jordan ;

Lentzsch, Suzanne .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (04) :277-283

[36] Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma [J].

Zhou, Hongmei ;

Zhang, Min ;

Jin, Yi ;

Lang, Xianghua .

HEMATOLOGY, 2025, 30 (01)

[37] High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies [J].

De Novellis, Danilo ;

Scala, Pasqualina ;

Giudice, Valentina ;

Selleri, Carmine .

CELLS, 2025, 14 (11)

[38] Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma [J].

Jakubowiak, Andrzej J. ;

Kumar, Shaji ;

Medhekar, Rohan ;

Pei, Huiling ;

Lefebvre, Patrick ;

Kaila, Shuchita ;

He, Jianming ;

Lafeuille, Marie-Helene ;

Cortoos, Annelore ;

Londhe, Anil ;

Mavros, Panagiotis ;

Lin, Thomas S. ;

Usmani, Saad Z. .

ONCOLOGIST, 2022, 27 (07) :E589-E596

[39] Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma [J].

Yang, Naery ;

Mun, Yeung Chul ;

Seong, Chu-Myong ;

Huh, Hee Jin ;

Huh, Jungwon .

ANNALS OF LABORATORY MEDICINE, 2018, 38 (02) :160-+

[40] Myc rearrangement redefines the stratification of high-risk multiple myeloma [J].

Jin, Xianghong ;

Li, Hui ;

Zhang, Dingding ;

Liu, Shuangjiao ;

Song, Yuhang ;

Zhang, Fujing ;

Li, Ziping ;

Zhuang, Junling .

CANCER MEDICINE, 2024, 13 (11)

← 1 2 3 4 5 →